Personal tools

Akute myeloische Leukämie

AML: Medigene CD-TCR-001

A Phase I/II, Open-Label, Non-Randomized, Multicentre, Dose-Escalation Clinical Trial with Control Group to Evaluate the Safety, Feasibility and Preliminary Efficacy of PRAME TCR modified T cells, MDG1011, in Subjects with High Risk Myeloid and Lymphoid Neoplasms.Read More

AML: UC02-123-01

Multicenter, open-label, adaptive design phase I trial with genetically modified T-cells carrying Universal Chimeric Antigen Receptors (UniCAR02-T) in combination with CD123 target module (TM123) for the treatment of patients with hematologic and lymphatic malignancies ...Read More

AML: Army 1

First in man study with MEN1112, a CD157 targeted monoclonal antibody, in relapsed or refractory Acute Myeloid LeukemiaRead More

AML: AMG 427 20170528

A Phase 1 First-in-human Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of AMG 427 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia.Read More

AML: GEM333-01

A Multicenter, Open-label, Dose-escalating, Phase I Trial with GEM333, a CD33 Targeted Bispecific Anti- body Engaging T-cells, in Relapsed or Refractory Acute Myeloid Leukemia.Read More